Prevalência do anticorpo da hepatite A em crianças e adolescentes com hepatopatia crônica

Ferreira, Cristina Helena Targa; Taniguchi, Adriano Nori Rodrigues; Vieira, Sandra Maria Gonçalves; Lima, Jorge; Silveira, Themis Reverbel da

doi:10.1590/s0021-75572002000600011

“…[16][17][18] In our research, the prevalence of antibodies against HAV among the 335 HIV exposed and/or infected children tested was 26% (Table 2). These data are compatible with figures published by Ferreira et al 19 in 2002, studying children and adolescents with chronic liver disease in the State of Rio Grande do Sul.…”

Section: Discussionsupporting

confidence: 93%

Prevalência de anticorpos contra o vírus da hepatite A em crianças e adolescentes expostos e/ou infectados pelo HIV

Gouvêa¹,

Moraes-Pinto²,

Machado³

et al. 2005

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objective: To evaluate the prevalence of hepatitis A virus antibodies in HIV-exposed and/or HIV-infected children and adolescents.Methods: Between September 1996 and August 2002, 352 patients (200 exposed, but not HIV-infected and 152 HIV exposed and infected) were included in this study. These children and adolescents (age ranged between 1 and 14 years) were all followed up at the Pediatric AIDS Clinic of the Federal University of São Paulo (UNIFESP) and had anti-HAV antibodies determined by a commercially available ELISA method (tests for total anti-HAV antibodies and specific IgM antibodies) (Dia Sorin and Radim). Statistical analyses were done with chi-squared and t test.Results: The prevalence of hepatitis A virus antibodies in HIV-infected and HIV-exposed, but uninfected patients was 34% and 19.7%, respectively. We noticed that in the age range between 2 years and 10 years, the group of HIVinfected children presented a higher prevalence of hepatitis A virus antibodies (35.5%) than the group of uninfected children (16.7%) (p = 0.005). In the HIV infected group, children from B and C categories had a prevalence of hepatitis A virus antibodies (40.5%) higher than N and A categories (24.1%) (p = 0.042). Mean age did not differ when children from B and C categories were compared with N and A categories (5.18 and 5.66 years, respectively) (p = 0.617). Conclusions:The prevalence of hepatitis A virus antibodies in HIV exposed and/or infected children and adolescents between 1 and 14 years old was 26%. Considering the possibility of HIV infection aggravation when associated with hepatitis A virus infection, we suggest that hepatitis A virus inactivated vaccine should be administered to these patients.

show abstract

“…6,17,33,34 Response to the vaccine was recently assessed in Porto Alegre, in children with Down syndrome and chronic hepatopathies. [35][36][37] Satisfactory seroconversion results were obtained, but with lower antibody titres than those in normal children in the same age group. The results are given in Tables 2 and 3 95.2%).…”

Section: Hepatitis a Vaccinementioning

confidence: 85%

Prevenção das hepatites virais através de imunização

Ferreira¹,

Silveira²

2006

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

Objective: To present an updated review and criticism of viral hepatitis A and B prevention by immunization. Summary of the findings: Viral hepatitis prevention is an enormous challenge to the public health systems of countries and the medical and scientific communities. Hepatitis viruses produce important morbimortality in the world, causing acute and chronic hepatic disease. There are highly efficient vaccines available on the market to prevent new infections by the A and B viruses. However, A and B viruses continue to be among the most commonly notified diseases preventable by vaccines. In this article, we discuss the vaccines used to prevent these infections, with the aim of expanding knowledge and the practice of prevention of these infectious diseases.Conclusions: Although the vaccines against A and B hepatitis are recommended for various risk groups, estimated vaccine coverage is still modest and many vaccination opportunities are lost. In order to reduce the incidence of A and B hepatitis, which are preventable by vaccines, it is necessary for physicians to encourage their patients to be vaccinated.

show abstract

“…Esses dados coincidem com os valores encontrados por Ferreira et al 19 , em 2002, estudando crianças e adolescentes com hepatopatia crônica no Rio Grande do Sul.…”

Section: Discussionunclassified

The prevalence of hepatitis A antibodies in HIV exposed and/or infected children and adolescents

Gouvêa¹,

Moraes-Pinto²,

Machado³

et al. 2005

View full text Add to dashboard Cite

Objective: To evaluate the prevalence of hepatitis A virus antibodies in HIV-exposed and/or HIV-infected children and adolescents.Methods: Between September 1996 and August 2002, 352 patients (200 exposed, but not HIV-infected and 152 HIV exposed and infected) were included in this study. These children and adolescents (age ranged between 1 and 14 years) were all followed up at the Pediatric AIDS Clinic of the Federal University of São Paulo (UNIFESP) and had anti-HAV antibodies determined by a commercially available ELISA method (tests for total anti-HAV antibodies and specific IgM antibodies) (Dia Sorin and Radim). Statistical analyses were done with chi-squared and t test.Results: The prevalence of hepatitis A virus antibodies in HIVinfected and HIV-exposed, but uninfected patients was 34% and 19.7%, respectively. We noticed that in the age range between 2 years and 10 years, the group of HIV-infected children presented a higher prevalence of hepatitis A virus antibodies (35.5%) than the group of uninfected children (16.7%) (p = 0.005). In the HIV infected group, children from B and C categories had a prevalence of hepatitis A virus antibodies (40.5%) higher than N and A categories (24.1%) (p = 0.042). Mean age did not differ when children from B and C categories were compared with N and A categories (5.18 and 5.66 years, respectively) (p = 0.617). Conclusions:The prevalence of hepatitis A virus antibodies in HIV exposed and/or infected children and adolescents between 1 and 14 years old was 26%. Considering the possibility of HIV infection aggravation when associated with hepatitis A virus infection, we suggest that hepatitis A virus inactivated vaccine should be administered to these patients. ResumoObjetivo: Avaliar a prevalência de anticorpos contra o vírus da hepatite A em crianças e adolescentes expostos e/ou infectados pelo HIV.Métodos: Entre setembro de 1996 e agosto de 2002, foram incluídos neste estudo 352 crianças e adolescentes, filhos de mães soropositivas para o HIV (200 expostos e não-infectados pelo HIV, e 152 expostos e infectados pelo HIV). Essas crianças e adolescentes, com idade entre 1 e 14 anos, acompanhados no Ambulatório de AIDS Pediátrica da Universidade Federal de São Paulo (UNIFESP), fizeram teste sorológico contra hepatite A como parte da avaliação de rotina. A dosagem de anticorpos anti-HAV (anticorpos totais e IgM) foi realizada através do método ELISA (Dia Sorin e Radim). A comparação das faixas etárias entre os grupos foi feita utilizando o teste do qui-quadrado e, para comparar as médias de idade das categorias clínicas entre as crianças infectadas, utilizou-se o teste t.Resultados: A prevalência de anticorpos contra o vírus da hepatite A foi de 34% nos pacientes infectados e expostos ao HIV e 19,7% no grupo de soro-revertidos (expostos ao HIV e não-infectados). Estratificando a amostra por faixa etária, observamos que, para as crianças de 2 a 10 anos, o grupo de infectados pelo HIV apresentou prevalência de anticorpos para o vírus hepatite A (35,5%) maior do que o gr...

show abstract

Prevalência do anticorpo da hepatite A em crianças e adolescentes com hepatopatia crônica

Cited by 6 publications

References 8 publications

Prevalência de anticorpos contra o vírus da hepatite A em crianças e adolescentes expostos e/ou infectados pelo HIV

Prevalência de anticorpos contra o vírus da hepatite A em crianças e adolescentes expostos e/ou infectados pelo HIV

Prevenção das hepatites virais através de imunização

The prevalence of hepatitis A antibodies in HIV exposed and/or infected children and adolescents

Contact Info

Product

Resources

About